A randomised trial of Mycobacterium w in critically ill patients with COVID-19: ARMY-1

PURPOSE: We investigated whether Mycobacterium w (Mw), an immunomodulator, would improve clinical outcomes in coronavirus disease 2019 (COVID-19). METHODS: We conducted an exploratory, randomised, double-blind, placebo-controlled trial of hospitalised subjects with severe COVID-19 (pulmonary infiltr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehgal, Inderpaul Singh, Guleria, Randeep, Singh, Sarman, Siddiqui, Mohammad Sabah, Agarwal, Ritesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942222/
https://www.ncbi.nlm.nih.gov/pubmed/34031642
http://dx.doi.org/10.1183/23120541.00059-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942222/
https://www.ncbi.nlm.nih.gov/pubmed/34031642
http://dx.doi.org/10.1183/23120541.00059-2021

Ejemplares similares